Post Reply
61-80 of 108
These are taken from OCBC report and company..Hopes it answers tradechancellors question..:)
Positive clinician feedback.
positive for LMA. When we visited the 18
held in Singapore (1-3 Mar 07), we were impressed by the positive feedback
from the end user clinicians on the ease of use and efficacy of the
Stonebreaker. We also investigated competing devices from Dornier
MedTech (shockwave technology), Lumenis (laser technology) and the
Swiss Lithoclast (pneumatic technology) and came away with the impression
that these machines cost more and/or took a longer period of time to break
stones (less efficient).
We view this diversification into urology asth Video Urology world congressEnergy delivery system.
Stonebreaker is the method which the device is able to transfer energy to
the tip of the probe which will be in contact with the stone. The kinetic
energy delivered to the stone then utilises the natural faults in the stone to
fragment it into manageable sized fragments for removal. There is minimal
probe movement thus reducing stone movement away from the probe
(retropulsion).
The key Intellectual Property (IP) behind the1
come from the sales of the device. With an average sale price of US$7500,
it comes much more affordable than other lithotripsy machines. Capital
good purchases typically have a threshold below US$10,000 so hospitals
or small urology centres will be able to easily get their hands on the
Stonebreaker without much paperwork. The Swiss Lithoclast has an
estimated installed base of about 5000 worldwide and we expect LMA to
be aggressive in taking its market share and to promote this in the Asian
region due to its portability and lower price point.
st phase revenue stream. The Stonebreaker?s 1st phase of revenue willPage 12 30 March 2007
LMA International NV
2
expect to see higher usage and thus an increase in revenue of the
consumable probes and CO2 cartridges. Management has highlighted that
these consumables are difficult to replicate for the Stonebreaker to deliver
the same performance. We note that the likelihood of re-use of probes is
more probable than buying cheaper 3
has mentioned that new flexible probes are being designed as an additional
offering to the present straight probe.
nd phase revenue stream. With an increase in the installed base, werd party consumables. ManagementEndorsement of product.
LMA has signed an exclusive distributorship agreement with EDAP. EDAP,
with more than 25 years of experience in sales and distribution, has a
strong knowledge of the medical community in France. The company has
significant expertise in the domestic lithotripsy market and a dedicated
distribution network.
As a show of quick marketing execution footwork,Current Stonebreaker capacity.
are able to produce Stonebreakers by the ?hundreds? from their Switzerland
plant but it would be simple to replicate the production line and thus
quadrupling capacity if necessary.
Management has indicated that theyForecast for Urology.
for the Urology segment. As guided, we forecast that the Stonebreaker will
grow exponentially from its small base to contribute about US$3m in FY07
and grow 120% YoY to contribute US$6.5m in FY08.
Management is confident of achieving strong growth3. Urology Products
Urology market potential.
addressing the urinary tract stone problem. Each year, more than 600k
Americans, mostly aged between 30 and 60 suffer from urolithiasis (the
process of stones forming in the kidney, bladder and/or urethra). These
stones range in consistency (soft to hard) and size (speck-sized to walnutsized).
LMA has opted to enter the urology market by?Stone hard? facts:
- 12% of Americans will have a kidney stone some time in their life
- Prevalence of urolithiasis in the American population is 5.2% (up
from 3.8% from 30 years ago)
- In 2000, 600k Americans went to the emergency room for stone
related pain
- 1/3 of all visits to a urologists are for kidney stones
- The development of the stones is related to decreased urine volume
or increased excretion of stone-forming components such as
calcium, oxalate, urate, cystine, xanthine, and phosphate. It is
expected to be increasingly prevalent.
Emerging markets are calling.
Pacific HQ in Singapore is due to the proximity of major emerging markets
of China (2.1b people) and India (1.1b people). Stone burden is large and
complex systems are costly and are only available at large hospitals,
rendering the majority of the rural population without an adequate solution.
The Stonebreaker will give urologists a compact, portable and self powered
device to address this huge rural need.
A primary reason that LMA has its Asia
To all who have faith in LMA,
Today's news comes as a surprise. Dont worry about those weak hands who sell or wish to clear their position. US is a big market and that is why US stock market has such great influence to the rest of the world.
Breaking into US market means more opportunity of selling more products there once they are certified.
Just keep faith and wait for it to cheong more in coming days.
Hi ten4one
Thanks for the excellent clarification. But, not all funds react that way. Some would have to sell down to test the market. After all, not all funds make money for their clients - some have been losing money .
BTW, selling down doesn't mean that the Funds aren't making money. This is just one of the many trading techniques FMs used - just to make the counter more dynamic.
FMs also have to maintain their reputations and ensure the funds they managed are at a healthy level - the more money they made for their clients, the more clients they'll have and more commissions.Cheers!
Hi jackjames
As most of us are not traders, we can't be as nimble as them. That's the beauty of being "fun (not fund) managers". As it is not their money that is at stake, they can just sell down whenever a share rises. At most they just forsake that counter if the price "runs away".
hope you are right.. but i do agreed with you this stock "hou cham" kena throw so badly..
it's about time to rise ba..
Hi jackjames
BBs are throwing , just like another fund which recently trimmed its holding of LMA shares @ 55cts even. They are betting that today's price won't hold for the next few days, lo. To the funds, they are not obliged to make money for their participants, so they can just sell down to test the market.
| 15:45:28 | 0.600 | 503,000 | Sell Down |
| 15:45:04 | 0.605 | 173,000 | Sell Down |
| 15:43:51 | 0.610 | 100,000 | Sell Down |
| 15:43:05 | 0.610 | 374,000 | Sell Down |
| 15:40:26 | 0.615 | 2,000 | Sell Down |
| 15:40:14 | 0.615 | 10,000 | Sell Down |
| 15:39:46 | 0.615 | 50,000 | Sell Down |
| 15:39:38 | 0.615 | 40,000 | Sell Down |
| 15:36:57 | 0.615 | 25,000 | Buy Up |
| 15:36:36 | 0.615 | 10,000 | Buy Up |
| 15:36:35 | 0.615 | 20,000 | Buy Up |
| 15:35:47 | 0.615 | 479,000 | Sell Down |
if this is so good, why some BB are throwing still? so confused lo..
price is still way cheap..remember that counter is way undervalued with respects to its fundamentals and growth potential..this might be the catalyst to swing counter back up up and away..and price is still way off ipo price of 88 cents..
more good news may be still in pipeline..still have abundant cash at hand for major acquisitions and growth opportunities.. :)
FDA approval in US, CE mark in Europe. No equivalent products in the world. Marketed to the world. This is going to be HUGE for LMA. Good thing I have loaded up to the hilt on this one.
what's ur average price hikitty? heee...
good for contra today...kekeke..
Surge up!!!
Congrats to all vested..esp hikitty!
FOR IMMEDIATE RELEASE
LMA receives FDA approval to market urology device LMA StoneBreaker
TMin the US
Singapore, 17 May 2007
development and marketing of the LMA
management devices, announced today that the Food and Drug Administration (?FDA?) has granted
approval for LMA to commence marketing the LMA StoneBreaker
The revolutionary and innovative system, manufactured in Switzerland, received the CE mark in June
2006. The effectiveness of this kinetic intracorporeal lithotripsy technique has been proven by a
peer-reviewed clinical trial and several hundred clinical cases to date. Sales of the device have
already commenced in Europe and Asia.
LMA Group President and CEO Michael Ashton said, ?We are extremely pleased with this latest
development. Based on the positive response and increasing demand for the device in other parts of
the world since its introduction last year, we anticipate demand from the US to fuel sales growth in
the second half of FY2007.?
The LMA StoneBreaker
stones in the urinary tract. This handheld system complements lithotripsy procedures performed with
extra-corporeal shockwave lithotripsy devices by targeting kidney stones located in places which
cannot be properly eliminated using this method.
? Mainboard-listed LMA International NV (?LMA?), the global leader in theTM laryngeal mask airway range of supraglottic airwayTM device in the United States.TM is a portable intra-corporeal contact lithotripter, which effectively fragments